Site Group Page
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Site Group Page
 

Site Information
53BP1 (human) T543-p IDEDGENtQIEDTEP Links 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 25, 26, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
53BP1 (mouse) T537-p TEEDRENtQIDDTEP Links 4, 18, 20, 21, 22, 23, 24, 27, 28, 29, 30, 31, 42, 43, 44

Records

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

4

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

5

(2011) CST Curation Set: 11376; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

6

(2011) CST Curation Set: 11379; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

7

(2011) CST Curation Set: 11381; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

8

(2011) CST Curation Set: 11116; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

9

(2011) CST Curation Set: 11115; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

10

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

11

(2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

12

(2010) CST Curation Set: 6271; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

13

(2010) CST Curation Set: 9957; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[st](phosphorylation)
Curated Info

14

(2010) CST Curation Set: 9961; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

15

(2010) CST Curation Set: 9960; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

16

(2010) CST Curation Set: 9962; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

17

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

18

(2010) CST Curation Set: 9668; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

19

(2010) CST Curation Set: 9294; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

20

(2009) CST Curation Set: 8561; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

21

(2009) CST Curation Set: 8562; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

22

(2009) CST Curation Set: 8560; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

23

(2009) CST Curation Set: 8558; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

24

(2009) CST Curation Set: 8556; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

25

(2009) CST Curation Set: 7976; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

26

(2009) CST Curation Set: 7978; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

27

(2009) CST Curation Set: 7168; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

(2009) CST Curation Set: 6932; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/MG132; Disease: leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

29

(2009) CST Curation Set: 6931; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

30

(2009) CST Curation Set: 6930; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

31

(2009) CST Curation Set: 6929; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/control; Disease: leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

32

(2009) CST Curation Set: 6439; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/control; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

33

(2009) CST Curation Set: 6440; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

34

(2009) CST Curation Set: 6454; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

35

(2009) CST Curation Set: 6455; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

36

(2009) CST Curation Set: 6452; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/control; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

37

(2009) CST Curation Set: 6437; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

38

(2009) CST Curation Set: 6450; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

39

(2009) CST Curation Set: 6438; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

40

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

41

(2008) CST Curation Set: 5762; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[st](phosphorylation)
Curated Info

42

(2008) CST Curation Set: 4462; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

43

(2008) CST Curation Set: 4463; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

44

(2008) CST Curation Set: 4464; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

45

(2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

46

Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A 104, 19855-60
18077418   Curated Info

47

(2007) CST Curation Set: 3481; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

48

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

49

(2007) CST Curation Set: 2927; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[st](phosphorylation)
Curated Info

50

(2007) CST Curation Set: 2934; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[st](phosphorylation)
Curated Info

51

(2006) CST Curation Set: 1772; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

52

(2006) CST Curation Set: 1773; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

53

(2006) CST Curation Set: 1774; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

54

(2006) CST Curation Set: 1775; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

55

(2006) CST Curation Set: 1616; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

56

(2005) CST Curation Set: 993; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/UV/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate (4F7) Rabbit mAb Cat#: 2909
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.